Chick Chorioallantoic Membrane Model and Precision Cancer Therapy

Coordinator: Tamanoi Fuyuhiko

Language: Anglais

Subject for Chick Chorioallantoic Membrane Model and Precision...

Approximative price 126.84 €

Not Yet Published

Add to cartAdd to cart
Publication date:
282 p. · 15.2x22.9 cm · Hardback
The Enzymes, highlights new advances in the field, with this new volume presenting interesting chapters

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in The Enzymes series

1. History of CAM model development Yoshio Endo 2. Overview of various CAM-based cancer models Fuyuhiko Tamanoi 3. The chick embryo chorioallantoic membrane as an in vivo experimental model to study multiple myeloma Domenico Ribatti 4. Bioluminescent CAM models for screening drugs against pancreatic cancer Elisa Giovannetti 5. X-ray sensitizer screen Yoshihiro Uto 6. Patient derived tumor model for esophageal cancer Manabu Muto 7. Renal cancer and metastasis Lily Wu 8. Nanoparticle characterization and tumor targeting Fuyuhiko Tamanoi 9. Patient derived tumor model for human nasopharyngeal carcinoma Zhe Zhang

Specialists in the field of Enzymes
Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997. Since 1996, he has been a Director of Signal Transduction Program Area at Jonsson Comprehensive Cancer Center. Dr. Tamanoi earned his B.S. and M.S. in Biochemistry at the University of Tokyo. He received PhD in Molecular Biology at Nagoya University in 1977. He was a postdoctoral fellow at Harvard Medical School, where he worked on bacteriophage DNA replication. From 1980 to 1985, he was a senior staff investigator at Cold Spring Harbor Laboratory, where he worked on adenovirus DNA replication. From 1985 to 1993, he was an Assistant Professor and then Associate Professor at the University of Chicago, where he initiated studies on lipid modification of the Ras family proteins. His laboratory research centers on signal transduction and signal transduction inhibitors. He is currently exploring ways to deliver signal transduction inhibitors using nanoparticles.